checkAd

    DGAP-Adhoc  650  0 Kommentare Cytos Biotechnology Ltd announces amendment of convertible loan notes agreement - Seite 2


    a potential new treatment for asthma.

    CYT003 has a novel mechanism of action that inhibits the immune response
    that causes asthma, and may therefore be beneficial for the control of
    asthma. In a successfully completed Phase 2a study, CYT003 was shown to
    maintain asthma control and lung function in patients with persistent
    allergic asthma, despite withdrawal of standard therapy with inhaled
    corticosteroids. CYT003 has been shown to have a good safety and
    tolerability profile in more than 450 individuals receiving the active
    agent so far.

    Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
    Technology (ETH) in Zurich. It is located in Schlieren (Zurich),
    Switzerland. The Company is listed according to the Main Standard on the
    SIX Swiss Exchange Ltd under the symbol CYTN.

    www.cytos.com

    Forward Looking Statements

    This media release contains certain forward-looking statements that involve
    risks and uncertainties that could cause actual results to be materially
    different from historical results or from any future results expressed or
    implied by such forward-looking statements. You are urged to consider
    statements that include the words "will" or "expect" or the negative of
    those words or other similar words to be uncertain and forward-looking.
    Factors that may cause actual results to differ materially from any future
    results expressed or implied by any forward-looking statements include
    scientific, business, economic and financial factors, including that CYT003
    may not demonstrate safety or efficacy in clinical trials, that there may
    be delays in development or that CYT003 may not receive marketing approval,
    and that the Company relies on outside financing to meet capital
    requirements, which may not be available under acceptable terms or at all.
    Against the background of these uncertainties, readers should not rely on
    forward-looking statements. The Company assumes no responsibility for
    updating forward-looking statements or adapting them to future events or
    developments.



    +++++
    Additional features:
    Document: http://n.equitystory.com/c/fncls.ssp?u=RVVUAVOKCB
    Document title: Cytos_Press_E_140331_convertible


    31.03.2014 News transmitted by EQS Schweiz AG.
    The issuer is responsible for the contents of the release.

    EquityStory publishes regulatory releases, media releases on the capital
    market and press releases.
    The EquityStory Group distributes authentic and real-time financial news
    for over 1'300 listed companies.
    The Swiss news archive can be found at www.equitystory.ch/news

    ---------------------------------------------------------------------------

    Language: English
    Company: Cytos Biotechnology AG
    Wagistr. 25
    8952 Schlieren
    Switzerland
    Phone: +41 44 733 4747
    Fax: +41 44 733 4740
    E-mail: info@cytos.com
    Internet: www.cytos.com
    ISIN: CH0011025217, CH0029060735
    Valor: -
    Listed: Freiverkehr in Berlin, München, Stuttgart;
    Frankfurt in Open Market ; SIX

    End of Announcement EQS Group News-Service

    ---------------------------------------------------------------------------

    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc Cytos Biotechnology Ltd announces amendment of convertible loan notes agreement - Seite 2 Cytos Biotechnology AG / Key word(s): Bond 31.03.2014 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR --------------------------------------------------------------------------- Cytos announces amendment of convertible loan notes …